A pharmaceutical developer has identified a promising
antibiotic candidate with potent activity against highly drug‑resistant
bacterial pathogens. While early laboratory and animal data are encouraging,
the team anticipates significant obstacles when designing Phase III clinical
trials compared with trials for infections caused by drug‑susceptible
organisms.

Which issue most plausibly accounts for these difficulties?

Question

A pharmaceutical developer has identified a promising
antibiotic candidate with potent activity against highly drug‑resistant
bacterial pathogens. While early laboratory and animal data are encouraging,
the team anticipates significant obstacles when designing Phase III clinical
trials compared with trials for infections caused by drug‑susceptible
organisms.

Which issue most plausibly accounts for these difficulties?

Accepted Answer

Ethical
and logistical considerations complicate trial design because patients must
still receive established effective therapies

Answer

Phase
III studies in resistant infections are limited to inferiority trial designs

Answer

Data
from in vitro and animal models are insufficient to justify advancement to late‑phase trials

Answer

Regulators
mandate that drugs for resistant infections must lack activity against non‑resistant bacteria

Crowdly

A pharmaceutical developer has identified a promising antibiotic candidate with...

Want instant access to all verified answers on learning.monash.edu?